Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Considering Blow-Fill-Seal for Biologic Drugs

April 02, 2022

The continuous, aseptic fill/finish process is finding use in vaccines and biologic drugs.

Meeting Challenges in Solid-Dose Packaging

April 02, 2022

Innovations address supply-chain constraints, serialization, and new requirements for sustainable and patient-centric designs.

Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines

March 10, 2022

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

Trends in Solid-Dose Packaging

March 08, 2022

Innovations address sustainable and patient-centric designs.

The Shape of Dosage Forms

March 03, 2022

Technological advances are helping shape the dosage forms of the future.

Successfully Accelerating Formulation Strategies

March 03, 2022

Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.

Process Performance as a Means of Quality Management

March 03, 2022

Process performance metrics of eight different mechanical devices were assessed to evaluate compliance with regulatory and compendial criteria.

Troubleshooting Using Predictive Maintenance

March 03, 2022

Smart manufacturing transforms management of tablet and capsule equipment and processes.

Biocon Biologics to Acquire Biosimilars Assets from Viatris in $3.3 Billion Deal

March 02, 2022

Biocon Biologics will acquire Viatris’ global biosimilars business, including the company’s portfolio of in-licensed biosimilar assets, in a transaction valued at over $3.3 billion.

AstraZeneca Progresses Ambition Zero Carbon Program with Honeywell Partnership to Develop Next-Generation Respiratory Inhalers

February 24, 2022

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.